Drug Type T cell engagers (TCE) |
Synonyms IAR 113, IAR113 |
Target |
Action stimulants, inhibitors |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), MUC16 inhibitors(Mucin-16 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
MUC16 Positive Malignancies | Preclinical | China | 28 Apr 2025 | |
Ovarian Cancer | Preclinical | China | 28 Apr 2025 |